Which company makes budesonide oral suspension (Eohilia)?

Budesonide oral suspension (Eohilia) is a glucocorticoid drug specially used to treat eosinophilic esophagitis and is suitable for patients 11 years old and above. The drug reduces esophageal inflammation through local anti-inflammatory effects and improves patients' swallowing function and quality of life. Eohilia is manufactured by Takeda Pharmaceuticals, a globally influential pharmaceutical company headquartered in Japan with extensive experience in drug development for respiratory and digestive system diseases. Takeda Pharmaceuticals strictly follows international GMP standards to produce drugs, ensuring that oral suspensions meet high standards in terms of drug uniformity, stability and safety.

Eohilia is unique in its oral suspension dosage form. After shaking, the medicinal solution will be in a thin and suspended state, which is easy to swallow. After passing through the esophagus, it will return to a thicker state, allowing budesonide to evenly cover the esophageal mucosa and achieve a local and sustained anti-inflammatory effect. This dosage form is particularly suitable for children and adolescent patients, avoiding the difficulties in taking traditional tablets or inhalants in children, while reducing the absorption of the drug throughout the body, thereby reducing the risk of systemic side effects.

In addition,Takeda continuously optimizes the suspension formula during the drug development process to improve the residence time of the drug on the esophageal surface and the persistence of anti-inflammatory effects, so that patients can obtain more stable symptom relief with regular medication. Clinical practice and overseas guidelines have emphasized that Eohilia's production standards and formulation technology ensure its consistency in safety, tolerability and efficacy, making it a reliable choice in the treatment of eosinophilic esophagitis.

To sum up, budesonide oral suspension is produced byTakeda Pharmaceuticals. Its advanced formulation technology, strict production management and dosage form design for children and adolescent patients make it both safe and effective in clinical application, providing a professional and convenient treatment option for patients with eosinophilic esophagitis.

Reference materials:https://www.eohilia.com/